跳至主要内容
临床试验/NCT03576716
NCT03576716已完成1 期

Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation

University of Washington1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2018年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
19
试验地点
1
主要终点
Change in Metabolic Clearance of D6-25(OH)D3

研究概览

简要总结

The goal of this study is to determine how 25(OH)D3 clearance is affected by vitamin D3 supplementation using a gold standard pharmacokinetic approach.

详细描述

We expect that this study will enhance interpretation of available diagnostic tests, inform the results of ongoing large clinical trials of vitamin D supplements, and help develop new strategies to target vitamin D to improve health.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Successful prior completion of related protocol CLEAR (NCT02937350) or CLEAR-CF (NCT03104855)
  • Age ≥ 18 years
  • Self-reported race Caucasian, African American, or African

排除标准

  • Primary hyperparathyroidism
  • Gastric bypass
  • Tuberculosis or sarcoidosis
  • Current pregnancy
  • Child-Pugh Class B or C cirrhosis (i.e. cirrhosis with ascites, hepatic encephalopathy, bilirubin >=2 mg/dL, serum albumin <=3.5 g/dL, or PT >= 4 seconds)
  • History of kidney transplantation (unless failed transplant now treated with hemodialysis)
  • Use of 1,25(OH)2D3 or an analogue, calcimimetics, or medications known to induce CYP24A1 within 4 weeks (wash-out allowed)
  • Serum calcium > 10.1 mg/dL
  • Hemoglobin < 10 g/dL

研究组 & 干预措施

Study Population

Experimental

D6-25-hydroxyvitamin D3 with vitamin D3

干预措施: D6-25-hydroxyvitamin D3 (Drug)

结局指标

主要结局

Change in Metabolic Clearance of D6-25(OH)D3

时间窗: Baseline, 6 months

Metabolic clearance is calculated as the administered dose of 25(OH)D3 divided by the area under the plasma concentration-time curve (AUC). AUC is calculated using the linear trapezoidal method. Change in clearance of D6-25(OH)D3 will be calculated as D6-25(OH)D3 clearance measured during CLEAR-PLUS minus D6-25(OH)D3 clearance previously measured during participation in the related study protocol (without vitamin D3 supplementation). Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration. The change listed is between two timepoints.

次要结局

  • Change in AUC of D6-25(OH)D3(Baseline, 6 months)
  • Change in Terminal Half-life of D6-25(OH)D3(Baseline, 6 months)
  • Change in Volume of Distribution of D6-25(OH)D3(Baseline, 6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ian deBoer

Professor, Medicine/Nephrology

University of Washington

研究点 (1)

Loading locations...

相似试验